Latest Tax Incentives News

Livium Ltd announces a further A$335,000 distribution from its 50% stake in the LieNA joint venture, following receipt of a substantial R&D tax incentive rebate for FY25. The joint venture remains well-funded through FY27, supporting ongoing lithium extraction technology development.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Small caps did the heavy lifting this week, led by two big discovery stories in resources. Funding raises and takeover moves kept attention on who can pay for the next step, not just promise it.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Redstone Resources has reported significant new high-grade copper intersections at unprecedented depths beneath its Tollu Copper deposit in Western Australia, hinting at a larger magmatic sulphide system. The company also secured government grants and raised capital to advance exploration.

EcoGraf Limited has marked significant progress in its Epanko Graphite Project financing and expansion plans, while initiating a strategic gold farm-in agreement with AngloGold Ashanti in Tanzania.

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.

Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.

Careteq Limited reported a disciplined operating cash flow in Q2 FY26 with strong growth in its Embedded Health Solutions segment and ongoing resolution of an ATO tax incentive dispute.

BluGlass Limited has extended its contract with the U.S. Department of War by A$1.05 million and appointed a refreshed Board to accelerate its commercial growth in visible laser technology. The company is advancing its GaN laser portfolio amid a US$100 million project pipeline and ongoing R&D investments.

Critica Limited has confirmed repeatable high-grade rare earth product quality at its Jupiter Project, delivering an 86% TREO concentrate and demonstrating gallium by-product potential. The company also secured an oversubscribed $8 million placement to fund pilot operations and a scoping study.